Analyst consensus rating
Telix Pharmaceuticals Analyst Rating: Strong Buy
TLX is rated Strong Buy by 4 analysts with a $21.18 target. As of 2026-08-25.
Direct answer
Telix Pharmaceuticals's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.18.
Forecast evidence checked August 25, 2026.
Get free Telix Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.68
- Average price target
- $21.18
- High price target
- $22.12
- Low price target
- $19.99
- Low target gap
- +71.2%
- Target upside
- +81.3%
- High target gap
- +89.4%
- Target range width
- 18.2%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Telix Pharmaceuticals?
Telix Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $21.18.
How far are Telix Pharmaceuticals's low and high targets from the recorded price?
The low target implies +71.2%, while the high target implies +89.4%.
How many analysts are included in Telix Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Telix Pharmaceuticals's target upside or downside calculated?
The average target of $21.18 is divided by the recorded price of $11.68, then one is subtracted to produce +81.3%. This does not guarantee a future return.
When was Telix Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.